Del tratamiento del cáncer a la enfermedad celíaca: Teva apunta a ingresos de 7 mil millones de dólares
El gigante farmacéutico israelí presentó un plan para aumentar los ingresos de medicamentos originales, mejorar los márgenes de rentabilidad y lanzar un medicamento innovador cada año • En el pipeline de desarrollo hay siete programas…
Valoración
Teva is laying out a growth plan that bets heavily on its pipeline of original drugs, not just generics. With seven advanced programs carrying a combined peak sales potential above $10 billion, the company is signaling it can return to serious revenue expansion. The target of $7 billion in sales and a new innovative drug launch each year sets a high bar. Watch whether the pipeline delivers on those peak projections, because that will determine if Teva can sustain the profitability improvements it also promised.